Anti-MRSA quinolones for acute bacterial skin and skin structure infection: a systematic review and meta-analysis of randomized controlled trials

References

• Russo A, Concia E, Cristini F, et al. Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections. Clin Microbiol Infect. 2016;22(Suppl 2):S27–36.
   PubMed Web of Science ®Google Scholar
• Golan Y. Current Treatment Options for Acute Skin and Skin-structure Infections. Clin Infect Dis. 2019;68(Supplement_3):S206–s12.
   PubMed Web of Science ®Google Scholar
• Edelsberg J, Taneja C, Zervos M, et al. Trends in US hospital admissions for skin and soft tissue infections. Emerg Infect Dis. 2009;15:1516–1518.
   PubMed Web of Science ®Google Scholar
• Mistry RD. Skin and Soft Tissue Infections in Ambulatory Care Settings: setting a New Trend. Clin Infect Dis. 2020;70(12):2719–2720.
   PubMed Web of Science ®Google Scholar
• Fritz SA, Shapiro DJ, Hersh AL. National Trends in Incidence of Purulent Skin and Soft Tissue Infections in Patients Presenting to Ambulatory and Emergency Department Settings, 2000-2015. Clin Infect Dis. 2020;70:2715–2718.
   PubMed Web of Science ®Google Scholar
• Lopez FA, Lartchenko S. Skin and soft tissue infections. Infect Dis Clin North Am. 2006;20(759–72):v–vi.
   Google Scholar
• Odell CA. Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) skin infections. Curr Opin Pediatr. 2010;22:273–277.
   PubMed Web of Science ®Google Scholar
• Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis. 2014;59:147–159.
   PubMed Web of Science ®Google Scholar
• Jaffa RK, Pillinger KE, Roshdy D, et al. Novel developments in the treatment of acute bacterial skin and skin structure infections. Expert Opin Pharmacother. 2019;20:1493–1502.
   PubMed Web of Science ®Google Scholar
• Chen C-W, Chang S-P, Huang H-T, et al. <p>The efficacy and safety of ceftaroline in the treatment of acute bacterial infection in pediatric patients – a systemic review and meta-analysis of randomized controlled trials. Infect Drug Resist. 2019;12:1303–1310.
   PubMed Web of Science ®Google Scholar
• Lan S-H, Lai -C-C, Lu L-C, et al. <p>Efficacy and safety of delafloxacin in the treatment of acute bacterial skin and skin structure infections: a systematic review and meta-analysis of randomized controlled trials. Infect Drug Resist. 2019;12:1415–1423.
   PubMed Web of Science ®Google Scholar
• Lan S-H, Lee H-Z, Lai -C-C, et al. Clinical efficacy and safety of ceftobiprole in the treatment of acute bacterial skin and skin structure infection: a systematic review and meta-analysis of randomized controlled trials. Expert Rev Anti Infect Ther 2021 1–8 Doi: https://doi.org/10.1080/14787210.2021.1927711
   Google Scholar
• Lan SH, Lin WT, and Chang SP, et al. Tedizolid Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection: a Systematic Review and Meta-Analysis. Antibiotics (Basel). 2019;8(3): 137.
   Web of Science ®Google Scholar
• Bell AM, King ST, Barber KE, et al. Newest lipoglycopeptides for the management of acute bacterial skin and skin structure infections. Nurse Practitioner. 2018;43(10):31–37.
   PubMed Web of Science ®Google Scholar
• Hsu CK, Chen CY, and Chen WC, et al. Clinical efficacy and safety of novel lipoglycopeptides in the treatment of acute bacterial skin and skin structure infections: a systematic review and meta-analysis of randomized controlled trials. Expert Rev Anti Infect Ther. 2021;1–10 doi:https://doi.org/10.1080/14787210.2022.1984880.
   Google Scholar
• Bhagwat SS, Nandanwar M, Kansagara A, et al. Levonadifloxacin, a Novel Broad-Spectrum Anti-MRSA Benzoquinolizine Quinolone Agent: review of Current Evidence. Drug Des Devel Ther. 2019;13:4351–4365.
   PubMed Web of Science ®Google Scholar
• Scott LJ. Delafloxacin: a Review in Acute Bacterial Skin and Skin Structure Infections. Drugs. 2020;80:1247–1258.
   PubMed Web of Science ®Google Scholar
• Bhatia A, Mastim M, Shah M, et al. Efficacy and Safety of a Novel Broad-Spectrum Anti-MRSA Agent Levonadifloxacin Compared with Linezolid for Acute Bacterial Skin and Skin Structure Infections: a Phase 3, Openlabel, Randomized Study. J Assoc Physicians India. 2020;68:30–36.
   PubMedGoogle Scholar
• Covington P, Davenport JM, Andrae D, et al. Randomized, double-blind, phase II, multicenter study evaluating the safety/tolerability and efficacy of JNJ-Q2, a novel fluoroquinolone, compared with linezolid for treatment of acute bacterial skin and skin structure infection. Antimicrob Agents Chemother. 2011;55:5790–5797.
   PubMed Web of Science ®Google Scholar
• Kingsley J, Mehra P, Lawrence LE, et al. A randomized, double-blind, Phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin. J Antimicrob Chemother. 2016;71(3):821–829.
   PubMed Web of Science ®Google Scholar
• O’Riordan W, McManus A, Teras J, et al. A Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin With Vancomycin Plus Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections: a Phase 3, Multinational, Double-Blind, Randomized Study. Clin Infect Dis. 2018;67(5):657–666.
   PubMed Web of Science ®Google Scholar
• O’Riordan W, Mehra P, Manos P, et al. A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections. Int J Infect Dis. 2015;30:67–73.
   PubMed Web of Science ®Google Scholar
• Pullman J, Gardovskis J, Farley B, et al. Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study. J Antimicrob Chemother. 2017;72(12):3471–3480.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement. J Clin Epidemiol. 2021;134:103–112.
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. Bmj. 2019;366:l4898.
   PubMed Web of Science ®Google Scholar
• Remy JM, Tow-Keogh CA, McConnell TS, et al. Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization. J Antimicrob Chemother. 2012;67(12):2814–2820.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Sader HS, and Rhomberg PR, et al. In Vitro Activity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014. Antimicrob Agents Chemother. 2017;61(4) :e02609–16.
   PubMed Web of Science ®Google Scholar
• Appalaraju B, Baveja S, Baliga S, et al. In vitro activity of a novel antibacterial agent, levonadifloxacin, against clinical isolates collected in a prospective, multicentre surveillance study in India during 2016-18. J Antimicrob Chemother. 2020;75:600–608.
   PubMed Web of Science ®Google Scholar
• Bakthavatchalam YD, Shankar A, Muniyasamy R, et al. Levonadifloxacin, a recently approved benzoquinolizine fluoroquinolone, exhibits potent in vitro activity against contemporary Staphylococcus aureus isolates and Bengal Bay clone isolates collected from a large Indian tertiary care hospital. J Antimicrob Chemother. 2020;75:2156–2159.
   PubMed Web of Science ®Google Scholar
• Farrell DJ, Liverman LC, Biedenbach DJ, et al. JNJ-Q2, a new fluoroquinolone with potent in vitro activity against Staphylococcus aureus, including methicillin- and fluoroquinolone-resistant strains. Antimicrob Agents Chemother. 2011;55:3631–3634.
   PubMed Web of Science ®Google Scholar
• Morrow BJ, He W, Amsler KM, et al. In Vitro Antibacterial Activities of JNJ-Q2, a New Broad-Spectrum Fluoroquinolone. Antimicrob Agents Chemother. 2010;54(5):1955–1964.
   PubMed Web of Science ®Google Scholar